These findings have also recently been extended to primary human breast tumors where differential enhancers binding of ERα and changes in transcriptional output have been associated with distinct clinical outcomes with respect to endocrine therapy [50, 51]. The gene discussed is ESR1; the disease is breast neoplasm.